Blogger, 22, battling cancer reveals she is in remission

Ashleigh Rimmer, of Colne in Lancashire, was told last July she had a form of blood cancer called Non-Hodgkin lymphoma. She announced her good news in her latest blog post.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSIONS: Our findings extended evidence for TFA intake and DLBCL risk but not for other NHL subtypes. Reduced TFA consumption through dietary choices or health policy measures may support prevention of DLBCL, an aggressive NHL subtype. PMID: 33022699 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - Category: Nutrition Authors: Tags: Am J Clin Nutr Source Type: research
AbstractPurposeThe majority of childhood, adolescent, and young adult cancer survivors (CAYACS) are at risk of late effects but may not receive long-term follow-up care for these. Here, we investigated (1) self-reported late effects, (2) long-term follow-up care, and (3) factors associated with receiving follow-up care in a population-based sample of Norwegian long-term CAYACS.MethodsSurvivors were identified by the Cancer Registry of Norway. All> 5-year survivors diagnosed between 1985 and 2009 with childhood cancer (CCS, 0 –18 years old, excluding CNS), breast cancer (BC, stages I–III), colorectal cancer (...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
We report two cases of BC and MCL, where the diagnosis of lymphoma was delayed due to misinterpretation of axillary lymph nodes (LNs).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Systemic Treatment Source Type: research
Publication date: December 2020Source: Cancer Epidemiology, Volume 69Author(s): Charlie Zhong, Meredith Franklin, Joseph Wiemels, Roberta McKean-Cowdin, Nadia T. Chung, Jennifer Benbow, Sophia S. Wang, James V. Lacey, Travis Longcore
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
AbstractPurposeFear of cancer recurrence (FCR) may be debilitating, yet knowledge of FCR among the growing population of long-term young adult cancer survivors (YACS) is scarce. We explored risk of FCR and associated factors in a nation-wide, population-based cohort of YACS.MethodsAll 5-year survivors diagnosed at the ages of 19 –39 years with breast cancer (BC), malignant melanoma (MM), colorectal cancer (CRC), leukemia (LEU), or non-Hodgkin lymphoma (NHL) between 1985 and 2009 in Norway were identified by the Cancer Registry of Norway and completed the cross-sectional comprehensive NOR-CAYACS health survey. Un...
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Authors: Balhorn R, Balhorn MC Abstract SH7139, the first of a series of selective high affinity ligand (SHAL) oncology drug candidates designed to target and bind to the HLA-DR proteins overexpressed by B-cell lymphomas, has demonstrated exceptional efficacy in the treatment of Burkitt lymphoma xenografts in mice and a safety profile that may prove to be unprecedented for an oncology drug. The aim of this study was to determine how frequently the HLA-DRs targeted by SH7139 are expressed by different subtypes of non-Hodgkin's lymphoma and by other solid cancers that have been reported to express HLA-DR. Binding stu...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Gnagnarella P, Raimondi S, Aristarco V, Johansson HA, Bellerba F, Corso F, Gandini S Abstract Increasing scientific evidence supports the link between vitamin D and cancer risk. The active metabolite 1,25(OH)2D exerts its activity by binding to the vitamin D receptor (VDR), an intracellular receptor that mediates transcriptional activation and repression of target genes. The binding of 1,25(OH)2D to VDR is able to regulate hundreds of different genes. VDR is active in virtually all tissues including the colon, breast, lung, ovary, bone, kidney, parathyroid gland, pancreatic b-cells, monocytes, T lymphocyte...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Blogging | Cancer | Cancer & Oncology | Health | Lymphoma | Non-Hodgkin's Lymphoma